Wuhan General Group Inc.

OTC: WUHN

Company Overview

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".

Financial Highlights

$80,376,752

Revenue (ttm)

$14,541,550

Gross Profit (ttm)

-$0.35

Diluted EPS (ttm)

Management Team

Ms. Carol Pan
Principal Financial Officer, Principal Accounting Officer and Treasurer

Mr. Jeffrey Robinson
Founder, Chairman & CEO

Mr. Willem Jonker
Chief Operating Officer

Dr. Hyder Ali Khoja A.Ag., M.Sc., Ph.D.
Chief Scientific Officer

Mr. Luka Marjanovic M.Sc.
Director of HR & Communication

Ms. Shivani Subudhi
Head of Marketing

Mr. Huang Zhaoqi
Vice Gen. Mang. of Turbine and Director

Dr. Anna Leralta Morera
Chief Medical Officer

Mr. Johann Mcloughlin
Head of Visual Comm. & Design

Mr. Samuel Williams
Head of Food Formulations & Functional Foods

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
()

Insider Ownership
0%